What is DNAe?
Founded in 2003 and headquartered in London, UK, DNAe is at the forefront of developing innovative semiconductor DNA sequencing technology. The company's core mission is to enable rapid, near-patient live diagnostics, providing clinicians with actionable information crucial for timely medical interventions. This technology holds the potential to revolutionize healthcare by bringing sophisticated genetic analysis closer to the point of care, thereby accelerating diagnosis and treatment planning.
How much funding has DNAe raised?
DNAe has raised a total of $38M across 1 funding round:
Debt
$38M
Debt (2015): $38M with participation from Citibank
Key Investors in DNAe
Citibank
Citibank, a leading global financial services institution, likely provided debt financing, supporting DNAe's operational and expansionary capital needs.
What's next for DNAe?
With a major strategic investment and substantial total funding, DNAe is well-positioned for its next phase of growth. The company is likely to focus on scaling its operations, further refining its semiconductor DNA sequencing platform, and expanding its market reach within the healthcare sector. This backing suggests a strong validation of DNAe's technology and its potential to address critical needs in rapid diagnostics, paving the way for broader adoption and impact in clinical settings.
See full DNAe company page
